YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)
Parker Waichman Alonso LLP Headlines by Topic
Tysabri
Tysabri PML Cases Get Attention of European Drug Agency
Aug 14, 2008 | Parker Waichman Alonso LLP
European health regulators are taking a hard look at two cases of a potentially lethal brain infection linked to the drug Tysabri. About 31,800...
Tysabri Lawsuit to Stay in State Court
Aug 8, 2008 | Parker Waichman Alonso LLP
A lawsuit over injuries allegedly caused by the multiple sclerosis drug, Tysabri, is staying in Massachusetts state court. The...
Tysabri Linked to More Cases of PML
Aug 1, 2008 | Parker Waichman Alonso LLP
Tysabri has been implicated in two more cases of a deadly brain infection, raising new concerns about the safety of the multiple sclerosis...
Tysabri Now Linked to Severe Liver Damage
Feb 27, 2008 | Parker Waichman Alonso LLP
Tysabri, a controversial drug used to treat Multiple Sclerosis (MS) manufactured by Biogen Idec Inc. and Elan Corp. has been linked to serious liver...
Tysabri Waltzes through FDA Advisory Panel by 12-0
Mar 9, 2006 | Newsinferno News Staff
When sales of Tysabri were suspended on February 28, 2005, many critics of the highly controversial MS drug, with potentially fatal side-effects,...
Tysabri - Opponents of MS Drug Linked to Potentially Fatal Brain Disease Locked In Emotional Debate with Desperate Patients before FDA Advisory Panel
Mar 8, 2006 | Newsinferno News Staff
Normally, the decision as to whether a prescription drug should be approved for marketing is based on scientific evidence and clinical studies....
FDA Official Still Wary About MS Drug
Mar 7, 2006 | AP
Some patients who take a promising multiple sclerosis drug will likely die of a rare brain infection if the medicine, Tysabri, is allowed back on the...
Anti-inflammatory Drugs Potentially Deadly Side Effect Found To Be Rare
Mar 3, 2006 | www.sciencedaily.com
Scientists have completed an extensive study of more than 3,000 patients who received a promising anti-inflammatory drug, natalizumab, that was...
Doctors wary of Biogen MS drug, survey says
Mar 1, 2006 | Boston Globe
Shares in Biogen Idec Inc. and Elan Corp. fell sharply yesterday after a Wall Street analyst published the results of a survey suggesting doctors...
Elan Stung by Research Report
Feb 28, 2006 | www.thestreet.com
Tysabri, the multiple sclerosis drug from Biogen Idec (BIIB:Nasdaq) and Elan (ELN:NYSE ADR) , should return to the market but with strict limitations...
Tysabri
